DS

Daniel Sharp

Alcidion Group Limited | Non-Executive Director
Mr Sharp has over 25 years of senior executive experience in investment banking and corporate finance. He was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two leading independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raising and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to networks of institutional, family office and net worth investors both in Australia and overseas. Danny is currently a Non-Executive Director of Botanix Pharmaceuticals and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation.

Company and Role

Company
Title
Tenure
Since
ALC
ALC
Alcidion Group Limited
  • Non-Executive Director
5yrs, 1mthSep 2021

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ALC
ALC
Alcidion Group Limited
30/06/26578,572800,000N/AN/A
BOT
BOT
30/06/26N/A6,075,791833,333N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
BOT
BOT
20/04/26
Issued
833,333$0.035$29,166Placement
BOT
BOT
10/04/26
Issued
833,333$0.060$49,999Placement
BOT
BOT
20/03/25
Issued
3,111,145$0.435$1,353,348Exercise of options
BOT
BOT
20/03/25
Exercise
4,000,000$0.435$1,740,000Exercise of options
BOT
BOT
02/12/24
Issued
3,000,000$0.350$1,050,000Issue of securities